Sequoia Capital

Zhongke Haishi is a high-tech enterprise specializing in the research and development, production and sales of new materials and their application in the field of temperature-regulating functional textiles.

NuProbe, Inc. is an early-stage molecular diagnostics company that focuses on noninvasive nucleic acid profiling and diagnostics. Founded in 2016 and based in Cambridge, Massachusetts, with an additional office in Shanghai, China, the company has developed a unique platform utilizing genetic toehold probes for quantitative PCR (qPCR) mutation detection. This innovative probe technology offers a Sample-In Answer-Out (SIAO) solution that integrates cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatics interpretations, streamlining the diagnostic process.

Full-Life Technologies Limited is a global company specializing in RadioTherapeutics, with its headquarters in Shanghai, China, and operations extending to Europe. The firm focuses on targeted cancer therapy services within the radiotherapy field, aiming to enhance treatment outcomes for cancer patients. Full-Life is dedicated to advancing nuclear medicine through innovative research in radiopharmaceuticals, which supports healthcare providers in delivering effective cancer treatments.

Neptune Robotics develops and manufactures underwater drones designed for enterprises in the maritime industry. Its underwater drones reduce the spread of invasive species in the ocean and also include filtration and debris collection systems designed to clean up oceans, enabling the reduction of waste in the oceans and improve ocean ecosystems.

Developer of an artificial intelligence platform designed to optimize pharmaceutical formulation processes. The company's software helps pharmaceutical companies accelerate the movement of new drugs in the pipeline through optimizing pre-clinical trial operations, enabling users to efficiently conduct research and design.

Alpha Cen is a developer of wafer-level metasurface light control chips and modules. It offers a semiconductor IC-compatible process to integrate micro-nano optical metasurfaces with circuits, light sources, and photodetectors.

Energy Singularity is a nuclear fusion technology company dedicated to advancing clean energy solutions. The company specializes in developing controllable nuclear fusion technology, focusing on high-magnetic field, high-parameter, standardized high-temperature superconducting tokamak devices. These innovations have the potential for commercial power generation and are supported by sophisticated operation control software systems. By pursuing these objectives, Energy Singularity aims to contribute to achieving energy freedom for humanity.

Upward Technology is a vibration solution controller. They offer research directions for magnetorheological materials. Their products include Vegehile Intelligent Suspension and Presence Equipment Active Vibration Isolators.

SceneRay Corporation, Limited is a medical device company based in Suzhou, China, specializing in the design, development, and distribution of neuromodulation devices. The company offers a range of products, including a deep brain stimulation system that features an implantable neuro-stimulator, patient controller, and various accessories. Additionally, SceneRay develops spinal cord stimulation and sacral nerve stimulation systems. The team at SceneRay comprises experts with extensive experience in neuromodulation device development, manufacturing, and marketing, and the company holds numerous patents in this field. Committed to advancing neuromodulation solutions, SceneRay aims to provide patients with high-quality and effective treatments.

Tongxin makes magnetically-suspended artificial blood pumps which are designed to replace the human heart. They are undergoing clinical trials in China after being fast-tracked through the approval process by the National Medical Products Administration, state-run Xinhua News Agency

NeuroXess is an invasive brain-computer interface with high-density flexible brain electrodes aimed at brain research and disease diagnosis.

Micro-nano core is committed to the development and production of the world's leading intelligent IoT AIoT SoC serialized chips, through the world's leading four core technologies: ultra-low-power chip architecture technology (to solve the problem of system standby power consumption), ultra-low power consumption Power consumption closed-loop adaptive near-threshold circuit technology (to solve the problem of chip running power consumption), ultra-low power consumption and high-precision sensor acquisition technology (to solve the problem of high precision and low power consumption of sensor signal acquisition) and high-efficiency embedded AI engine technology (solving the computing power and energy efficiency of embedded AI), creating a general/platform technology system for IoT chips and AIoT serialized chips, enabling IoT products, and significantly improving the low power consumption, low power consumption, and low power consumption of future IoT products High-precision detection and edge AI inference performance.

Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd., founded in 2012 and located in Zhengjiawu, China, specializes in researching and developing innovative drugs for metabolic diseases and breast cancer. The company focuses on addressing conditions such as Non-Alcoholic SteatoHepatitis (NASH), gout, diabetes, and colon cancers. By concentrating on metabolism and inflammation, Atom Bioscience aims to provide more effective treatment options for patients suffering from these ailments, enhancing the quality of care in the healthcare sector.

Dangsheng New Material is a high-performance fiber material developer and a high-tech enterprise dedicated to the development, production and sales of high-performance fiber materials. It has realized the production of China's only high-performance anti-virus and biochemical barrier protective clothing made of a single material. . Dangsheng New Materials provides a series of medical disposable protective products, including protective clothing, isolation clothing, protective shoe covers and other supplies.

Developer of an artificial intelligence platform designed to optimize pharmaceutical formulation processes. The company's software helps pharmaceutical companies accelerate the movement of new drugs in the pipeline through optimizing pre-clinical trial operations, enabling users to efficiently conduct research and design.

Shanghai Duoning Biotechnology Co., Ltd. specializes in the development of serum-free, personalized, and chemically defined cell culture media for the biopharmaceutical industry. Founded in 2005 and based in Shanghai, the company offers a range of products, including basic media, feed media, and cell therapy media. Duoning Biotech is dedicated to providing tailored media development, cell culture process optimization, and commissioned formula production services, utilizing its expertise in animal cell culture concepts. The company supports the research, development, and commercialization of biologics products by delivering comprehensive solutions that encompass technical support and customized services tailored to the needs of pharmaceutical and scientific research institutions.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

Provider of nanotechnology equipment and services intended for pan-semiconductor and new energy enterprises. The company provides advanced nanomaterial thin film deposition manufacturing equipment and services that could be used in the fields of chips, semiconductors and lithium batteries, enabling clients with high-quality nano thin firm deposition equipment.

Developer of gene sequencing technology designed to promote the development of precision medicine. The company's business scope covers software and hardware for sequencers, sample processing, consumables, reagents and data processing, enabling genetic sequencing to be a routine detection and diagnostic tool for medical industry.

Cellular Biomedicine Group is a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases utilizing proprietary cell therapy technologies. It is the result of the acquisition, transfer, commercialization, and advancement of thirty years of research and human treatment experience in cellular medicine. Its cellular research and development is the result of collaboration among scientists and doctors from the US, England, and China.

GenEdit Inc. is a biotechnology company based in Berkeley, California, established in 2016. It specializes in developing innovative genome editing technologies, particularly using the CRISPR/Cas9 system for therapeutic gene editing. The company focuses on addressing the challenges associated with the delivery of gene therapies through its proprietary non-viral nanoparticle-based delivery platform. This platform enables more efficient and accurate delivery of CRISPR components, enhancing the potential for curative treatments for genetic diseases. By systematically screening a library of nanoparticles, GenEdit aims to improve the safety and effectiveness of gene editing, making it a promising solution for a wide range of therapeutic applications.

Nreal Ltd., founded in 2017 and based in Beijing, China, specializes in the development of augmented reality (AR) and mixed reality (MR) technologies, primarily focusing on wearable devices. The company's flagship product, Nreal Light, is recognized as the first lightweight and comfortable mixed reality glasses, featuring a vivid display and advanced spatial computing algorithms that deliver an immersive user experience. Nreal aims to democratize mixed reality, making it accessible to a broader audience while encouraging developers to create innovative applications that enhance entertainment, productivity, and other sectors. The company's technology incorporates SLAM-based environment-understanding AI algorithms, further enriching the user experience through interactive and engaging applications.

neoX BIOTECH is a biotechnology company that develops antigen-based cancer vaccine through a deep understanding of biophysics and the use of artificial intelligence. It develops a neoantigen prediction and TCR screening platform. The company was founded in 2018 and is based in Beijing, China.

Stemirna Therapeutics Co., Ltd. is a biotechnology company based in Shanghai, China, founded in 2016. The company specializes in developing mRNA technology-based drug solutions, with a focus on personalized cancer vaccines, mRNA vaccines for infectious diseases, and treatments for genetic and protein defect diseases. Stemirna has established a comprehensive mRNA drug platform that includes a GMP production center and a tumor neoantigen library, along with a clinical cooperation platform for mRNA drug development. With more than a dozen independently-developed projects, Stemirna aims to harness the potential of RNA science to provide safe and effective therapeutic options for patients suffering from various medical conditions.

Analytical Biosciences focuses on the development of single-cell genome technologies to enhance the understanding and treatment of human diseases. By collaborating with medical research institutions, hospitals, and pharmaceutical companies, the company leverages single-cell genomics and bioinformatics to create detailed maps of diseases. This approach allows for large-scale systematic disease mapping and the mining of extensive data sets, which aids partners in identifying new therapeutic targets and formulating innovative treatment strategies. Analytical Biosciences employs high-resolution databases and advanced data analytics to facilitate the discovery and validation of novel cellular targets and biomarkers, ultimately contributing to the development of next-generation therapeutics and diagnostics.

Phanes Therapeutics, Inc. is a biotechnology company based in San Diego, California, established in 2016. It specializes in the discovery and development of therapeutics aimed at treating solid tumors and eye diseases. The company's portfolio includes a monoclonal antibody designed for solid tumors and various ophthalmic conditions such as age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. Additionally, Phanes Therapeutics is developing a bispecific antibody targeting small cell lung cancer. With a focus on scientific innovation, the company strives to create advanced therapeutic options that enhance patient care and improve lives worldwide.

Developer and researcher of innovative drugs for vision treatment designed to cure topical diseases. The company focuses on delivering new therapies to millions of patients living with chronic ocular or dermal inflammatory diseases by combining world-class expertise and promising drug targets, providing best-in-class therapeutics and pharmaceuticals for the treatment of dry eye syndromes and atopic dermatitis.

PackGene Biotech, LLC develops viral vectors for gene therapies. The company offers adeno-associated virus (AAV) vector cloning/packaging services. PackGene Biotech, LLC is based in the United States.

Neuracle is a well-known enterprise in the field of neuroscience in China. They rely on Tsinghua University's independent innovation and international leading "brain-machine interface" technology, and are committed to innovative research in the fields of neuroscience, psychology, neuroengineering, etc., providing professional and complete solutions for the diagnosis, treatment and rehabilitation of clinical neurological diseases. Program. Their products cover a wide range of fields including clinical medicine, neuroscience, psychology, management marketing, etc., and take the lead in undertaking the National Twelfth Five-Year Science and Technology Support Program. The research and development results and products have been experts in neuroscience and clinical medicine at home and abroad. widely accepted.

PatSnap Pte. Ltd. operates an AI-powered Software-as-a-Service platform focused on intellectual property (IP) analytics and management. This platform is designed to assist users, even those without IP expertise, in navigating their competitive landscape by providing insights into upcoming innovations and new product opportunities. It enables users to conduct patent searches, analyze market trends, monitor competition, and manage their IP portfolios effectively. The platform features a variety of graphical analysis tools, including heat maps and citation maps, to help users visualize and interpret data. PatSnap serves a diverse clientele, including corporations, research institutions, and government agencies across various sectors such as technology, life sciences, and manufacturing. Founded in 2007 and headquartered in Singapore, PatSnap has additional offices in Los Angeles, London, Beijing, Suzhou, and Shanghai, allowing it to cater to a global audience.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

neoX BIOTECH is a biotechnology company that develops antigen-based cancer vaccine through a deep understanding of biophysics and the use of artificial intelligence. It develops a neoantigen prediction and TCR screening platform. The company was founded in 2018 and is based in Beijing, China.

Jifan Biotechnology is a biotechnology firm that provides molecular biology reagents, diagnostic raw materials, and kits for research.

Novotech is Australia’s largest independent CRO. The Australian Head Office is in Sydney, with regional offices in Melbourne and Brisbane - providing easy access to the most important population centers in Australia. Supported by regional staff across the country and in New Zealand, our coverage of the Australia/New Zealand region is comprehensive. With Asian services launched in 2007, Novotech’s operations provide access to the most dynamic and fast growing clinical research hubs in the region.

NuProbe, Inc. is an early-stage molecular diagnostics company that focuses on noninvasive nucleic acid profiling and diagnostics. Founded in 2016 and based in Cambridge, Massachusetts, with an additional office in Shanghai, China, the company has developed a unique platform utilizing genetic toehold probes for quantitative PCR (qPCR) mutation detection. This innovative probe technology offers a Sample-In Answer-Out (SIAO) solution that integrates cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatics interpretations, streamlining the diagnostic process.

SciNeuro Pharmaceuticals develops medicines for patients with central nervous system (CNS) diseases. The company is based in Shanghai, China.

PackGene Biotech, LLC develops viral vectors for gene therapies. The company offers adeno-associated virus (AAV) vector cloning/packaging services. PackGene Biotech, LLC is based in the United States.

Nanjing SemiDrive Technology Ltd. is a semiconductor company based in Nanjing, China, established in 2018. The firm specializes in designing and manufacturing core processor chips for the automotive industry, focusing on applications such as advanced driver assistance systems (ADAS) and autonomous driving. Its product lineup includes the X9 chip for high-performance eCockpit applications, the V9 chip for ADAS and autonomous driving, and the G9 chip, which serves as a vehicle central gateway connecting multiple domains. SemiDrive also offers research and development services for intelligent core processors and provides system-level turnkey solutions. The company operates with a fabless manufacturing model, with additional R&D facilities in Beijing and an office in Shenzhen, addressing the growing demand for smart driving technologies and high-performance industrial microprocessors in the automotive sector.

Nreal Ltd., founded in 2017 and based in Beijing, China, specializes in the development of augmented reality (AR) and mixed reality (MR) technologies, primarily focusing on wearable devices. The company's flagship product, Nreal Light, is recognized as the first lightweight and comfortable mixed reality glasses, featuring a vivid display and advanced spatial computing algorithms that deliver an immersive user experience. Nreal aims to democratize mixed reality, making it accessible to a broader audience while encouraging developers to create innovative applications that enhance entertainment, productivity, and other sectors. The company's technology incorporates SLAM-based environment-understanding AI algorithms, further enriching the user experience through interactive and engaging applications.

neoX BIOTECH is a biotechnology company that develops antigen-based cancer vaccine through a deep understanding of biophysics and the use of artificial intelligence. It develops a neoantigen prediction and TCR screening platform. The company was founded in 2018 and is based in Beijing, China.

Yunjing (Narwal) Intelligence Technology (Dongguan) Co., Ltd. designs, develops, and produces intelligent cleaning robots. The company offers Narwal T10, a self-cleaning robot cleaner for automated mop cleaning, floor cleaning, and smart mapping. The company was founded in 2016 and is headquartered in Dongguan, China with an additional office in Shenzhen, China.

Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd., founded in 2012 and located in Zhengjiawu, China, specializes in researching and developing innovative drugs for metabolic diseases and breast cancer. The company focuses on addressing conditions such as Non-Alcoholic SteatoHepatitis (NASH), gout, diabetes, and colon cancers. By concentrating on metabolism and inflammation, Atom Bioscience aims to provide more effective treatment options for patients suffering from these ailments, enhancing the quality of care in the healthcare sector.

SiBionics is medtech comppany specialized in the R&D and commercialization of active implantable medical devices and medical artificial intelligence. The company is based in Shenzhen, China.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

Nuanwa Technology is a health insurance technology platform. The company is positioned in the field of health insurance technology, mainly serving insurance companies and Internet platforms, providing products customization services, risk control, claims services, system services and other solutions for its health insurance business. Medical ecology and health insurance, open up barriers to medical data information.

Nuanwa Technology is a health insurance technology platform. The company is positioned in the field of health insurance technology, mainly serving insurance companies and Internet platforms, providing products customization services, risk control, claims services, system services and other solutions for its health insurance business. Medical ecology and health insurance, open up barriers to medical data information.

Burning Rock Biotech Limited is a cancer diagnostics company based in China that specializes in developing and providing next-generation sequencing (NGS) based cancer therapy selection tests. Founded in 2014 and headquartered in Guangzhou, the company offers a portfolio of 13 tests applicable to various cancer types, including lung, gastrointestinal, and breast cancers, utilizing both tissue and liquid biopsy samples. Notable products include OncoScreen Plus, which targets therapy and immunotherapy biomarkers, and LungPlasma, a liquid biopsy test for non-small cell lung cancer. Additionally, Burning Rock provides services for gastrointestinal cancer testing and assessments of genes related to homologous recombination deficiency. The company collaborates with major pharmaceutical firms such as AstraZeneca and Bayer on clinical trials and research studies, focusing on companion diagnostics and laboratory services. With a commitment to personalized cancer treatment, Burning Rock aims to deliver comprehensive solutions that integrate genetic testing with clinical and research services.

GenEdit Inc. is a biotechnology company based in Berkeley, California, established in 2016. It specializes in developing innovative genome editing technologies, particularly using the CRISPR/Cas9 system for therapeutic gene editing. The company focuses on addressing the challenges associated with the delivery of gene therapies through its proprietary non-viral nanoparticle-based delivery platform. This platform enables more efficient and accurate delivery of CRISPR components, enhancing the potential for curative treatments for genetic diseases. By systematically screening a library of nanoparticles, GenEdit aims to improve the safety and effectiveness of gene editing, making it a promising solution for a wide range of therapeutic applications.

PatSnap Pte. Ltd. operates an AI-powered Software-as-a-Service platform focused on intellectual property (IP) analytics and management. This platform is designed to assist users, even those without IP expertise, in navigating their competitive landscape by providing insights into upcoming innovations and new product opportunities. It enables users to conduct patent searches, analyze market trends, monitor competition, and manage their IP portfolios effectively. The platform features a variety of graphical analysis tools, including heat maps and citation maps, to help users visualize and interpret data. PatSnap serves a diverse clientele, including corporations, research institutions, and government agencies across various sectors such as technology, life sciences, and manufacturing. Founded in 2007 and headquartered in Singapore, PatSnap has additional offices in Los Angeles, London, Beijing, Suzhou, and Shanghai, allowing it to cater to a global audience.

Kneron, Inc. specializes in designing and developing integrated software and hardware solutions for edge artificial intelligence (AI). Founded in 2015 and headquartered in San Diego, California, with additional offices in Taiwan and China, Kneron provides a range of products including neural processing units (NPUs), AI System-on-Chips (SoCs), and visual recognition software. These solutions cater to various applications such as smart homes, smart surveillance, smartphones, robots, drones, and Internet of Things (IoT) devices. Kneron's technology enables real-time recognition, inference, and analysis without the need for a cloud connection, facilitating quick deployment of AI applications across different sectors. The company's goal is to enhance everyday devices with AI capabilities, contributing to the development of an Edge AI network.

Refuge Biotechnologies, Inc. is a Menlo Park, California-based company focused on developing cancer immunotherapies. Established in 2015, it utilizes synthetic biology and gene-editing technology, specifically CRISPR-dCas, to create innovative treatments. The company's approach involves engineering cell therapies that can sense their environment and simultaneously activate or repress multiple genes. This strategy aims to enhance the effectiveness and precision of cancer treatments, moving beyond traditional methods that target a single function. Through its research and development efforts, Refuge Biotechnologies is dedicated to advancing cancer diagnostics and therapies to improve patient outcomes.

NuProbe, Inc. is an early-stage molecular diagnostics company that focuses on noninvasive nucleic acid profiling and diagnostics. Founded in 2016 and based in Cambridge, Massachusetts, with an additional office in Shanghai, China, the company has developed a unique platform utilizing genetic toehold probes for quantitative PCR (qPCR) mutation detection. This innovative probe technology offers a Sample-In Answer-Out (SIAO) solution that integrates cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatics interpretations, streamlining the diagnostic process.

ThinkForce is a Shanghai-based company specializing in the production of artificial intelligence semiconductors. The firm develops intelligent semiconductors that integrate advanced AI algorithms and hardware platforms, focusing on creating specialist multi-core processors designed for high parallel processing capabilities. These processors consist of numerous simpler, independent cores, allowing clients to utilize chip virtualization services that function as a central processing unit for multiple independent computers. With a strong technical team, ThinkForce is committed to ensuring the successful integration of its technologies into various industrial applications.

Kneron, Inc. specializes in designing and developing integrated software and hardware solutions for edge artificial intelligence (AI). Founded in 2015 and headquartered in San Diego, California, with additional offices in Taiwan and China, Kneron provides a range of products including neural processing units (NPUs), AI System-on-Chips (SoCs), and visual recognition software. These solutions cater to various applications such as smart homes, smart surveillance, smartphones, robots, drones, and Internet of Things (IoT) devices. Kneron's technology enables real-time recognition, inference, and analysis without the need for a cloud connection, facilitating quick deployment of AI applications across different sectors. The company's goal is to enhance everyday devices with AI capabilities, contributing to the development of an Edge AI network.

Burning Rock Biotech Limited is a cancer diagnostics company based in China that specializes in developing and providing next-generation sequencing (NGS) based cancer therapy selection tests. Founded in 2014 and headquartered in Guangzhou, the company offers a portfolio of 13 tests applicable to various cancer types, including lung, gastrointestinal, and breast cancers, utilizing both tissue and liquid biopsy samples. Notable products include OncoScreen Plus, which targets therapy and immunotherapy biomarkers, and LungPlasma, a liquid biopsy test for non-small cell lung cancer. Additionally, Burning Rock provides services for gastrointestinal cancer testing and assessments of genes related to homologous recombination deficiency. The company collaborates with major pharmaceutical firms such as AstraZeneca and Bayer on clinical trials and research studies, focusing on companion diagnostics and laboratory services. With a commitment to personalized cancer treatment, Burning Rock aims to deliver comprehensive solutions that integrate genetic testing with clinical and research services.

Nanjing Dimension 5 Network Technology Co., Ltd. specializes in developing virtual reality solutions for the home furnishing and design industries in China and internationally. Founded in 2015 and based in Nanjing, the company provides a technical service platform that enhances service scenarios for design professionals. Its flagship product, D5-Fusion, is a software-as-a-service (SaaS) tool that enables space designers to transform their concepts into immersive 3D virtual environments. This innovative software allows interior designers to create real-time, VR-ready designs that clients can experience using virtual reality goggles, thereby revolutionizing the traditional interior design process.

PatSnap Pte. Ltd. operates an AI-powered Software-as-a-Service platform focused on intellectual property (IP) analytics and management. This platform is designed to assist users, even those without IP expertise, in navigating their competitive landscape by providing insights into upcoming innovations and new product opportunities. It enables users to conduct patent searches, analyze market trends, monitor competition, and manage their IP portfolios effectively. The platform features a variety of graphical analysis tools, including heat maps and citation maps, to help users visualize and interpret data. PatSnap serves a diverse clientele, including corporations, research institutions, and government agencies across various sectors such as technology, life sciences, and manufacturing. Founded in 2007 and headquartered in Singapore, PatSnap has additional offices in Los Angeles, London, Beijing, Suzhou, and Shanghai, allowing it to cater to a global audience.

GenEdit Inc. is a biotechnology company based in Berkeley, California, established in 2016. It specializes in developing innovative genome editing technologies, particularly using the CRISPR/Cas9 system for therapeutic gene editing. The company focuses on addressing the challenges associated with the delivery of gene therapies through its proprietary non-viral nanoparticle-based delivery platform. This platform enables more efficient and accurate delivery of CRISPR components, enhancing the potential for curative treatments for genetic diseases. By systematically screening a library of nanoparticles, GenEdit aims to improve the safety and effectiveness of gene editing, making it a promising solution for a wide range of therapeutic applications.

Nio Limited is a prominent electric vehicle manufacturer based in Shanghai, China, focusing on the premium segment of the market. Founded in 2014, the company designs, jointly manufactures, and sells smart electric vehicles, including five, six, and seven-seater SUVs. Nio is recognized for its innovative technology, including battery swapping and autonomous driving features, which enhance user experience. Its model lineup includes the ES8, a high-performance seven-seater SUV launched in 2018, the ES6 five-seater SUV, and the EC6 electric coupe SUV. The company also provides a range of charging solutions, such as home charging, battery swapping services, and mobile charging options, alongside value-added services like insurance and maintenance. In addition to its electric vehicle offerings, Nio collaborates with organizations like Mobileye N.V. to advance its technology. As of 2023, Nio has sold over 160,000 electric vehicles, capturing approximately 2% of the new energy vehicle market in China.

Niu Technologies specializes in designing, manufacturing, and selling electric scooters, motorcycles, bicycles, and kick-scooters. Founded in 2014 and headquartered in Shanghai, China, the company offers a diverse range of products under the NIU brand, including its popular NQi, MQi, and UQi electric scooter series, as well as urban commuter motorcycles and professional bicycles. Niu also provides various accessories, such as safety gear and performance upgrades, alongside services through its NIU app, which includes repair requests, maintenance, and insurance. The company operates through a network of city partners, franchised stores, and third-party e-commerce platforms, with a strong presence in China and expanding international markets. As of late 2019, Niu had over 1,000 franchised stores and partnerships in approximately 180 cities across China and had established distribution in multiple countries worldwide.

Zai Lab Limited is a Shanghai-based biopharmaceutical company founded in 2013, dedicated to discovering, developing, and commercializing innovative therapeutics for oncology, autoimmune, and infectious diseases. The company offers several proprietary products, including Niraparib for treating solid tumors, Optune for glioblastoma multiforme, and Ripretinib for KIT and PDGFRa-driven cancers. Additionally, Zai Lab develops other investigational therapies such as REGN1979, Margetuximab, INCMGA0012, Bemarituzumab, Omadacycline, and Durlobactam. With a focus on the Chinese market, Zai Lab has established partnerships with leading global biopharmaceutical firms to enhance its drug pipeline and improve access to transformative medicines. The company leverages its expertise in drug development and favorable regulatory conditions in China, along with in-house manufacturing capabilities, to support both clinical and commercial production. Zai Lab aims to expand its operations and build a specialized commercial team to effectively market its products in China and beyond.

Burning Rock Biotech Limited is a cancer diagnostics company based in China that specializes in developing and providing next-generation sequencing (NGS) based cancer therapy selection tests. Founded in 2014 and headquartered in Guangzhou, the company offers a portfolio of 13 tests applicable to various cancer types, including lung, gastrointestinal, and breast cancers, utilizing both tissue and liquid biopsy samples. Notable products include OncoScreen Plus, which targets therapy and immunotherapy biomarkers, and LungPlasma, a liquid biopsy test for non-small cell lung cancer. Additionally, Burning Rock provides services for gastrointestinal cancer testing and assessments of genes related to homologous recombination deficiency. The company collaborates with major pharmaceutical firms such as AstraZeneca and Bayer on clinical trials and research studies, focusing on companion diagnostics and laboratory services. With a commitment to personalized cancer treatment, Burning Rock aims to deliver comprehensive solutions that integrate genetic testing with clinical and research services.

Zai Lab Limited is a Shanghai-based biopharmaceutical company founded in 2013, dedicated to discovering, developing, and commercializing innovative therapeutics for oncology, autoimmune, and infectious diseases. The company offers several proprietary products, including Niraparib for treating solid tumors, Optune for glioblastoma multiforme, and Ripretinib for KIT and PDGFRa-driven cancers. Additionally, Zai Lab develops other investigational therapies such as REGN1979, Margetuximab, INCMGA0012, Bemarituzumab, Omadacycline, and Durlobactam. With a focus on the Chinese market, Zai Lab has established partnerships with leading global biopharmaceutical firms to enhance its drug pipeline and improve access to transformative medicines. The company leverages its expertise in drug development and favorable regulatory conditions in China, along with in-house manufacturing capabilities, to support both clinical and commercial production. Zai Lab aims to expand its operations and build a specialized commercial team to effectively market its products in China and beyond.

Natera is a diagnostic and research company specializing in genetic testing services, primarily focused on preconception and prenatal testing. Its flagship product, Panorama, is a non-invasive prenatal test that screens for chromosomal abnormalities in fetuses through a blood draw from the mother, including assessments for twin pregnancies. Other offerings include Vistara, which tests for single-gene disorders, and Horizon carrier screening to identify carrier status for various genetic diseases. Natera also provides the Anora test for analyzing fetal chromosomes in cases of miscarriage and non-invasive paternity testing. Additionally, the company has developed Signatera, a technology that detects circulating tumor DNA to monitor cancer recurrence. Natera utilizes a direct sales force and a network of approximately 100 laboratory and distribution partners for product distribution. The company was founded in 2003, has undergone several name changes, and is headquartered in San Carlos, California. Its collaborations with organizations like BGI Genomics and Foundation Medicine further enhance its capabilities in genetic testing and personalized medicine.

Nio Limited is a prominent electric vehicle manufacturer based in Shanghai, China, focusing on the premium segment of the market. Founded in 2014, the company designs, jointly manufactures, and sells smart electric vehicles, including five, six, and seven-seater SUVs. Nio is recognized for its innovative technology, including battery swapping and autonomous driving features, which enhance user experience. Its model lineup includes the ES8, a high-performance seven-seater SUV launched in 2018, the ES6 five-seater SUV, and the EC6 electric coupe SUV. The company also provides a range of charging solutions, such as home charging, battery swapping services, and mobile charging options, alongside value-added services like insurance and maintenance. In addition to its electric vehicle offerings, Nio collaborates with organizations like Mobileye N.V. to advance its technology. As of 2023, Nio has sold over 160,000 electric vehicles, capturing approximately 2% of the new energy vehicle market in China.

Zai Lab Limited is a Shanghai-based biopharmaceutical company founded in 2013, dedicated to discovering, developing, and commercializing innovative therapeutics for oncology, autoimmune, and infectious diseases. The company offers several proprietary products, including Niraparib for treating solid tumors, Optune for glioblastoma multiforme, and Ripretinib for KIT and PDGFRa-driven cancers. Additionally, Zai Lab develops other investigational therapies such as REGN1979, Margetuximab, INCMGA0012, Bemarituzumab, Omadacycline, and Durlobactam. With a focus on the Chinese market, Zai Lab has established partnerships with leading global biopharmaceutical firms to enhance its drug pipeline and improve access to transformative medicines. The company leverages its expertise in drug development and favorable regulatory conditions in China, along with in-house manufacturing capabilities, to support both clinical and commercial production. Zai Lab aims to expand its operations and build a specialized commercial team to effectively market its products in China and beyond.

Natera is a diagnostic and research company specializing in genetic testing services, primarily focused on preconception and prenatal testing. Its flagship product, Panorama, is a non-invasive prenatal test that screens for chromosomal abnormalities in fetuses through a blood draw from the mother, including assessments for twin pregnancies. Other offerings include Vistara, which tests for single-gene disorders, and Horizon carrier screening to identify carrier status for various genetic diseases. Natera also provides the Anora test for analyzing fetal chromosomes in cases of miscarriage and non-invasive paternity testing. Additionally, the company has developed Signatera, a technology that detects circulating tumor DNA to monitor cancer recurrence. Natera utilizes a direct sales force and a network of approximately 100 laboratory and distribution partners for product distribution. The company was founded in 2003, has undergone several name changes, and is headquartered in San Carlos, California. Its collaborations with organizations like BGI Genomics and Foundation Medicine further enhance its capabilities in genetic testing and personalized medicine.

Koncen BioScience was founded by a group of Chinese who returned to the country after completing their educations overseas. This high-technology biomedical enterprise offers integrated research and development, along with manufacturing and marketing services, all focused on blood purification technologies and products.

Natera is a diagnostic and research company specializing in genetic testing services, primarily focused on preconception and prenatal testing. Its flagship product, Panorama, is a non-invasive prenatal test that screens for chromosomal abnormalities in fetuses through a blood draw from the mother, including assessments for twin pregnancies. Other offerings include Vistara, which tests for single-gene disorders, and Horizon carrier screening to identify carrier status for various genetic diseases. Natera also provides the Anora test for analyzing fetal chromosomes in cases of miscarriage and non-invasive paternity testing. Additionally, the company has developed Signatera, a technology that detects circulating tumor DNA to monitor cancer recurrence. Natera utilizes a direct sales force and a network of approximately 100 laboratory and distribution partners for product distribution. The company was founded in 2003, has undergone several name changes, and is headquartered in San Carlos, California. Its collaborations with organizations like BGI Genomics and Foundation Medicine further enhance its capabilities in genetic testing and personalized medicine.

Shanghai Newsummit Biopharma is a Chinese provider of comprehensive pharmaceuticals industrialization, modularization, standardization, and large-scale R&D services. Newsummit is focused on the optimization and integration of industrial resources through the alliance of governance, production, education, research and capital, to serve scientists, entrepreneurs, investors, and the government. These services include assisting the scientists to facilitate the achievements of new medicine and realize the industrialization; providing entrepreneurs with achievements with industrial value and industry incubation; helping investors to shorten investment cycle and reduce investment risk; serving the government by integrating resources from China's New Medicines Public Service Platform; and strengthening the international competitiveness of China's New Medicines' self-research and development.

Natera is a diagnostic and research company specializing in genetic testing services, primarily focused on preconception and prenatal testing. Its flagship product, Panorama, is a non-invasive prenatal test that screens for chromosomal abnormalities in fetuses through a blood draw from the mother, including assessments for twin pregnancies. Other offerings include Vistara, which tests for single-gene disorders, and Horizon carrier screening to identify carrier status for various genetic diseases. Natera also provides the Anora test for analyzing fetal chromosomes in cases of miscarriage and non-invasive paternity testing. Additionally, the company has developed Signatera, a technology that detects circulating tumor DNA to monitor cancer recurrence. Natera utilizes a direct sales force and a network of approximately 100 laboratory and distribution partners for product distribution. The company was founded in 2003, has undergone several name changes, and is headquartered in San Carlos, California. Its collaborations with organizations like BGI Genomics and Foundation Medicine further enhance its capabilities in genetic testing and personalized medicine.

Natera is a diagnostic and research company specializing in genetic testing services, primarily focused on preconception and prenatal testing. Its flagship product, Panorama, is a non-invasive prenatal test that screens for chromosomal abnormalities in fetuses through a blood draw from the mother, including assessments for twin pregnancies. Other offerings include Vistara, which tests for single-gene disorders, and Horizon carrier screening to identify carrier status for various genetic diseases. Natera also provides the Anora test for analyzing fetal chromosomes in cases of miscarriage and non-invasive paternity testing. Additionally, the company has developed Signatera, a technology that detects circulating tumor DNA to monitor cancer recurrence. Natera utilizes a direct sales force and a network of approximately 100 laboratory and distribution partners for product distribution. The company was founded in 2003, has undergone several name changes, and is headquartered in San Carlos, California. Its collaborations with organizations like BGI Genomics and Foundation Medicine further enhance its capabilities in genetic testing and personalized medicine.

Natera is a diagnostic and research company specializing in genetic testing services, primarily focused on preconception and prenatal testing. Its flagship product, Panorama, is a non-invasive prenatal test that screens for chromosomal abnormalities in fetuses through a blood draw from the mother, including assessments for twin pregnancies. Other offerings include Vistara, which tests for single-gene disorders, and Horizon carrier screening to identify carrier status for various genetic diseases. Natera also provides the Anora test for analyzing fetal chromosomes in cases of miscarriage and non-invasive paternity testing. Additionally, the company has developed Signatera, a technology that detects circulating tumor DNA to monitor cancer recurrence. Natera utilizes a direct sales force and a network of approximately 100 laboratory and distribution partners for product distribution. The company was founded in 2003, has undergone several name changes, and is headquartered in San Carlos, California. Its collaborations with organizations like BGI Genomics and Foundation Medicine further enhance its capabilities in genetic testing and personalized medicine.

China Nuokang Bio-Pharmaceutical Inc. is a fully integrated, profitable bio-pharmaceutical company focused on researching, developing, manufacturing and marketing hematological and cardiovascular products. They sell a portfolio of fourteen products, which includes principal products Baquting®, a flagship hemocoagulase, and Aiduo®, a cardiovascular stress imaging agent. There product pipeline includes product candidates under development in hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention.

Navigenics, Inc. helps educate and empower individuals and their physicians with knowledge of their genetic predispositions, and then motivates them to act on the information to prevent the onset of disease, achieve earlier diagnosis, appropriately manage disease, or otherwise lessen its impact. Navigenics' lead investors are Kleiner Perkins Caufield and Byers, Sequoia Capital and MDV-Mohr Davidow Ventures.

A123 Systems is a prominent developer and manufacturer of advanced lithium-ion batteries and energy storage systems. The company leverages innovative nanoscale materials initially developed at MIT to create its proprietary Nanophosphate electrode technology, which offers significant advantages over competing high-power technologies. A123's battery cells and electrode designs are engineered to reduce costs per watt and per watt-hour, while also providing higher voltage compared to other long-life battery systems. This results in lower overall pack costs and enhanced price-performance due to the batteries' long lifespan, which minimizes lifecycle costs. A123 Systems serves clients across various industries by delivering efficient power solutions that increase battery life and safety in electronic devices. Competitors in the space include Valence, Saft, and Lion Cells.

A123 Systems is a prominent developer and manufacturer of advanced lithium-ion batteries and energy storage systems. The company leverages innovative nanoscale materials initially developed at MIT to create its proprietary Nanophosphate electrode technology, which offers significant advantages over competing high-power technologies. A123's battery cells and electrode designs are engineered to reduce costs per watt and per watt-hour, while also providing higher voltage compared to other long-life battery systems. This results in lower overall pack costs and enhanced price-performance due to the batteries' long lifespan, which minimizes lifecycle costs. A123 Systems serves clients across various industries by delivering efficient power solutions that increase battery life and safety in electronic devices. Competitors in the space include Valence, Saft, and Lion Cells.

Narzana Technologies designs and develops mobile entertainment content.

A123 Systems is a prominent developer and manufacturer of advanced lithium-ion batteries and energy storage systems. The company leverages innovative nanoscale materials initially developed at MIT to create its proprietary Nanophosphate electrode technology, which offers significant advantages over competing high-power technologies. A123's battery cells and electrode designs are engineered to reduce costs per watt and per watt-hour, while also providing higher voltage compared to other long-life battery systems. This results in lower overall pack costs and enhanced price-performance due to the batteries' long lifespan, which minimizes lifecycle costs. A123 Systems serves clients across various industries by delivering efficient power solutions that increase battery life and safety in electronic devices. Competitors in the space include Valence, Saft, and Lion Cells.

Navini Networks specializes in providing portable, plug-n-play broadband wireless access solutions in the United States. The company offers a range of pre-Mobile WiMAX products, including the Ripwave MX product line, which features portable base stations, modems, radio frequency combiners, and element management systems. In addition, Navini Networks develops Smart WiMAX technology, which incorporates beamformed MIMO and smart beamforming to enhance mobile broadband services. Founded in 2000 and headquartered in Richardson, Texas, Navini Networks aims to deliver effective broadband solutions to the mass market.

Navini Networks specializes in providing portable, plug-n-play broadband wireless access solutions in the United States. The company offers a range of pre-Mobile WiMAX products, including the Ripwave MX product line, which features portable base stations, modems, radio frequency combiners, and element management systems. In addition, Navini Networks develops Smart WiMAX technology, which incorporates beamformed MIMO and smart beamforming to enhance mobile broadband services. Founded in 2000 and headquartered in Richardson, Texas, Navini Networks aims to deliver effective broadband solutions to the mass market.

Navini Networks specializes in providing portable, plug-n-play broadband wireless access solutions in the United States. The company offers a range of pre-Mobile WiMAX products, including the Ripwave MX product line, which features portable base stations, modems, radio frequency combiners, and element management systems. In addition, Navini Networks develops Smart WiMAX technology, which incorporates beamformed MIMO and smart beamforming to enhance mobile broadband services. Founded in 2000 and headquartered in Richardson, Texas, Navini Networks aims to deliver effective broadband solutions to the mass market.

Navini Networks specializes in providing portable, plug-n-play broadband wireless access solutions in the United States. The company offers a range of pre-Mobile WiMAX products, including the Ripwave MX product line, which features portable base stations, modems, radio frequency combiners, and element management systems. In addition, Navini Networks develops Smart WiMAX technology, which incorporates beamformed MIMO and smart beamforming to enhance mobile broadband services. Founded in 2000 and headquartered in Richardson, Texas, Navini Networks aims to deliver effective broadband solutions to the mass market.

Navini Networks specializes in providing portable, plug-n-play broadband wireless access solutions in the United States. The company offers a range of pre-Mobile WiMAX products, including the Ripwave MX product line, which features portable base stations, modems, radio frequency combiners, and element management systems. In addition, Navini Networks develops Smart WiMAX technology, which incorporates beamformed MIMO and smart beamforming to enhance mobile broadband services. Founded in 2000 and headquartered in Richardson, Texas, Navini Networks aims to deliver effective broadband solutions to the mass market.

Avanex was an optical components company designing and manufacturing optical components primarily for fiber-optic communication networks.

Avanex was an optical components company designing and manufacturing optical components primarily for fiber-optic communication networks.

Onyx Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for cancer treatment. The company's lead product, Nexavar (sorafenib), is an oral multiple kinase inhibitor that targets proteins associated with tumor cell growth and blood vessel formation. By aiming to improve the lives of individuals affected by cancer, Onyx Pharmaceuticals is dedicated to advancing cancer care through its therapeutic offerings.

Vical's core technology grew out of a chance discovery and provided the cornerstones for two new biopharmaceutical industry sectors: DNA vaccines and non-viral gene therapy. Vical's management systematically leveraged that technology into a broad portfolio of independent and partnered product development programs. The first products for animal health are on the market. The first human products are approaching.